Lepercq De Neuflize Asset Management LLC

Name: Lepercq De Neuflize Asset Management LLC 13F holdings, Q1 2025
Creator: Lepercq De Neuflize Asset Management LLC
Published: 2025-05-13

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q4 2024

In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 13, 2025), Lepercq De Neuflize Asset Management LLC reported 13 stock positions worth $103.3 million. Its top holding was SS SPDR S&P 500 ETF Trust-US (SPY) at 62.4% of the portfolio, followed by iShares MSCI Eafe ETF (EFA, 36.9%) and Lifecore Biomedical (LFCR, 0.1%). Compared with Q4 2024, it opened 2 new positions, sold out of 2, added to 3 and reduced 1. The biggest buy was a new position in AN2 Therapeutics (ANTX) and the biggest sale an exit from Invesco QQQ Trust Series 1 (QQQ).

Most Recent 13F: Q2 2026
Location: NEW YORK, NY
CIK: 0001854423
Portfolio Value: $103.3M (Q1 2025)
SEC Filing: 0001420506-25-000994 ↗ filed May 13, 2025

Holdings Value

Holdings 13 stocks · $103.3M


SPY SS SPDR S&P 500 ETF Trust-US	62.41%	115,245	$64.5M	No change
EFA iShares MSCI Eafe ETF	36.87%	466,000	$38.1M	No change
LFCR Lifecore Biomedical Inc.	0.13%	19,700	$139K	Reduce -13.2%
XYLO Xylo Technologies Ltd.	0.12%	26,059	$128K	No change
WETH Wetouch Technology Inc.	0.10%	67,954	$99K	No change
CLAR Clarus Corp.	0.08%	22,200	$83K	Add +5.7%
SQFT Presidio Property Trust - A	0.07%	134,125	$77K	No change
ENZB Enzo Biochem Inc.	0.06%	156,303	$58K	Add +27.1%
EPIX Essa Pharma Inc.	0.05%	31,700	$50K	Add +5.0%
ANTX AN2 Therapeutics Inc.	0.03%	23,234	$32K	New
LVTX Lava Therapeutics NV	0.03%	23,000	$29K	New
BRN Barnwell Industries Inc.	0.02%	15,000	$24K	No change
DSWL Deswell Industries Inc.	0.02%	10,000	$24K	No change

Other holdings (1): bonds, preferreds, convertibles and warrants · $8K (not counted above)

Security	Class	Shares / Principal	Value	Change
LGL.WS LGL Group Inc./the -CW25	*W EXP 11/16/202	26,200	$8K	No change

Total filed on the 13F, all lines: $103.3M.

Portfolio Sells Q4 2024 → Q1 2025


QQQ Invesco QQQ Trust Series 1	Sold out	0.00%	−16.96
ACWI iShares MSCI Acwi ETF	Sold out	0.00%	−8.79
LFCR Lifecore Biomedical Inc.	Reduce -13.2%	0.13%	+0.01

Portfolio Buys Q4 2024 → Q1 2025


ANTX AN2 Therapeutics Inc.	New	0.03%	+0.03
LVTX Lava Therapeutics NV	New	0.03%	+0.03
CLAR Clarus Corp.	Add +5.7%	0.08%	+0.01
EPIX Essa Pharma Inc.	Add +5.0%	0.05%	+0.01
ENZB Enzo Biochem Inc.	Add +27.1%	0.06%	−0.01

All Filings

Quarter	Positions	13F Reported Value	Top Holdings
Q2 2026	11	$156.6M	SPY, VOO, EFA, CTWO, QRVO
Q1 2026Amended	10	$137.5M	SPY, VOO, EFA, CTWO, SVCO
Q4 2025Amended	8	$174.7M	SPY, VOO, EFA, QRVO, CTWO
Q3 2025	9	$173.3M	SPY, VOO, EFA, MX, QRVO
Q2 2025	9	$114.5M	SPY, EFA, QRVO, XYLO, CLAR
Q1 2025	13	$103.3M	SPY, EFA, LFCR, XYLO, WETH
Q4 2024	13	$139.5M	SPY, EFA, QQQ, ACWI, LFCR